Arbutus Biopharma Corporation (ABUS) Earnings History
Annual and quarterly earnings data from 1998 to 2025
Loading earnings history...
ABUS EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ABUS Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 0.0% | -271.0% | -237.9% |
| 2024 | 100.0% | -1236.7% | -1133.0% |
| 2023 | 100.0% | -430.5% | -401.6% |
| 2022 | 100.0% | -167.8% | -178.0% |
| 2021 | 100.0% | -669.1% | -693.9% |
Download Data
Export ABUS earnings history in CSV or JSON format
Free sign-in required to download data
Arbutus Biopharma Corporation (ABUS) Earnings Overview
As of May 8, 2026, Arbutus Biopharma Corporation (ABUS) reported trailing twelve-month net income of -$34M, reflecting +55.3% year-over-year growth. The company earned $-0.17 per diluted share over the past four quarters, with a net profit margin of -237.9%.
Looking at the long-term picture, ABUS's historical earnings data spans multiple years. The company achieved its highest annual net income of $30M in fiscal 2012.
Arbutus Biopharma Corporation is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including REPL (-$315M net income), ASMB (-$6M net income, -8.5% margin), HBIO (-$57M net income, -65.5% margin), ABUS has comparable earnings metrics. Compare ABUS vs REPL →
ABUS Earnings vs Peers
Earnings metrics vs comparable public companies
ABUS Historical Earnings Data (1998–2025)
28 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$34M | +52.1% | -$38M | $-0.17 | -237.9% | -271.0% |
| 2024 | -$70M | +4.0% | -$76M | $-0.38 | -1133.0% | -1236.7% |
| 2023 | -$73M | -4.9% | -$78M | $-0.44 | -401.6% | -430.5% |
| 2022 | -$69M | +8.9% | -$65M | $-0.46 | -178.0% | -167.8% |
| 2021 | -$76M | -19.6% | -$74M | $-0.73 | -693.9% | -669.1% |
| 2020 | -$64M | +58.5% | -$58M | $-0.86 | -922.0% | -836.1% |
| 2019 | -$154M | -169.2% | -$144M | $-2.69 | -2557.4% | -2394.0% |
| 2018 | -$57M | +32.3% | -$90M | $-1.03 | -967.8% | -1522.0% |
| 2017 | -$84M | +78.0% | -$111M | $-1.54 | -788.8% | -1036.4% |
| 2016 | -$384M | -528.4% | -$492M | $-7.24 | -25606.7% | -32773.3% |
See ABUS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ABUS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ABUS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonABUS — Frequently Asked Questions
Quick answers to the most common questions about buying ABUS stock.
Is ABUS growing earnings?
ABUS EPS is $-0.17, with earnings growth accelerating to +55.3%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-34M.
What are ABUS's profit margins?
Arbutus Biopharma Corporation net margin is -237.9%, with operating margin at -271.0%. Below-average margins reflect competitive or cost pressures.
How consistent are ABUS's earnings?
ABUS earnings data spans 1998-2025. The accelerating earnings trend is +55.3% YoY. Historical data enables comparison across business cycles.